OS Fund
VC Fund
Park Ridge, United States
OS Fund is a VC fund in Park Ridge focused on Biotechnology and Health Care. The OS Fund finances and supports inventors and scientists who are working on audacious breakthroughs to solve the greatest issues and opportunities facing humanity today. Our mission is to partner with tech pioneers who aim to improve the lives of billions of people around the world for generations to come.In the same way that computers haveoperating systems at their core — dictating the way a computer works and serving as a foundation upon which all applications are built — everything in life has an operating system (OS).
- Total investments:
- 48
- Last investment:
- Lead investor:
- 15%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries OS Fund invests in
Stages OS Fund invests in
Countries OS Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.6M–$6M
- Series A
- $5M–$32M
- Series B
- $12M–$53M
Investment Focus
Industry
- Biotechnology 22 (46%)
- Health Care 12 (25%)
- Health Diagnostics 6 (13%)
- Medical 5 (10%)
- Artificial Intelligence 5 (10%)
Stage
- Series A 14 (29%)
- Seed 12 (25%)
- Series B 10 (21%)
- Series C 2 (4%)
- Series D 2 (4%)
Country
- United States 32 (67%)
- Canada 2 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bryan Johnson
Co-Founder & General Partner
|
Co-Founder & General Partner | Total investments: 8 | Find email | |
Daniel Robinson
Partner
|
Partner | Total investments: 0 | Find email | |
Jonathan Yaffe
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
Lily Kim
Partner
|
Partner | Total investments: 0 | Find email | |
Mark Ghobrial
Partner
|
Partner | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Arzeda
|
Arzeda develops innovative products powered by its Intelligent Protein Design Technology, using generative AI-driven design to create, validate, and manufacture new proteins and enzymes that enhance our lives and protect our planet. Arzeda commercializes with Fortune 500 go-to-market partners across multiple industries, enabling higher-performing,more cost-effective solutions that are healthier and sustainable. | $36.7M / Series B / Mar 29, 2022 | |
Kenota Health
|
Kenota Health develops next-generation rapid point-of-care system intended to be used for allergy testing in humans. Kenota's diagnostic tools are safe, simple, and offer a cheaper alternative to allergy testing using a thorough non-invasive technology, enabling physicians to improve patient outcomes. | $9M / Series A / Dec 07, 2020 | |
A-Alpha Bio
|
A-Alpha Bio provides cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio's product, AlphaSeq, is a revolutionary cell-based platform technology that will fundamentally change the way that proteininteractions are measured.A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. | $2.8M / Seed / Sep 24, 2019 | |
GRO Biosciences
|
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars. | $3.5M / Seed / Mar 13, 2019 | |
uBiome
|
uBiome is a citizen science startup that sequences the human microbiome. As the first and largest successful crowdsourced citizen science project in history, we allow the public access to cutting edge sequencing technology and are building a data platform to gather, analyze, and translate data about the human microbiome. We have developed thefirst sequencing-based, clinical microbiome tests and are committed to empowering patients and their healthcare providers to understand and take greater control of their health. We provide actionable insights and information to help foster understanding about the microbiome and the role it plays in health and wellness.union's mission is to transform research into useful products based on the microbiome.uBiome is the world’s first effort to map the human microbiome with citizen science.While the sequencing of the human genome has provided invaluable knowledge, it is very difficult to change their own genetic makeup. The microbiome, in contrast, is much more easily changed through simple means such as healthful probiotic cultures and other lifestyle interventions. The microbiome thus may provide some of the most important medical breakthroughs of their era. uBiome will ultimately empower participants to manage their microbiomes to improve their health as well as make important scientific discoveries for humanity. | $83M / Series C / Sep 21, 2018 | |
Verge Genomics
|
Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created abreakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease. | $32M / Series A / Jul 17, 2018 | |
Lygos - Better Materials for Better Products
|
Lygos is providing biotechnology solutions for today’s renewable chemical challenges. They engineer microbes to convert sugars into high-value, industrial chemicals, targeting compounds where biological production is cost-advantaged over petrochemical production. The company's throughput screening and strain construction facilitate the rapidoptimization of pathways to convert cheap and renewable feedstock to high-value chemicals.Founded in 2011, Lygos is headquartered in Berkeley, California. | $15.5M / Series B / Jul 17, 2018 | |
Catalog
|
Catalog is a developer of a data conversion and storage platform used to offer the next generation of digital data archives and computation. Its platform facilitates the encoding of data and information into DNA format and makes it economically attractive to use DNA as the major medium for long-term archival of data that enables customers to storedigital information in DNA molecules. It brings cutting-edge synthetic biology technologies to the world of information storage and computation.The company was founded in 2016 and is headquartered in Boston, Massachusetts. | $4M / Seed / Jun 26, 2018 | |
NuMat Technologies
|
NuMat Technologies builts an Operating System for the commercialization of programmable chemistries. It is creating the future of precision engineering by designing and building molecularly-programmed systems that unlock paradigm shifts in resource creation and use. The company's expertise lies in the design and integration of MOFs intonext-generation storage, separation, and purification systems. In doing so, NuMat enables previously unachievable form factors, performance and cost-advantaged production economics. NuMat provides a total solutions platform for product commercialization, pairing world-class material discovery software with application development and manufacturing expertise. | $12.4M / Series B / Apr 26, 2018 | |
Aria Pharmaceuticals
|
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel small molecule therapies for complex and hard-to-treat diseases. Too many patients today are in need of breakthrough treatments across many complicated diseases – they can't wait. That's why at Aria, we have redefined the drug discoveryapproach, saving years in the process and increasing success rates 30 times higher than traditional methods. At Aria, we've shown promise across a diverse range of therapeutic areas with the ability to address over 1,000 diseases. | $10M / Series A / Mar 19, 2018 | |
| See all 48 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does OS Fund invest in?
OS Fund invests primarily in Biotechnology, Health Care and Health Diagnostics startups, most often at Series A and Seed stage. Most of the 48 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is OS Fund's check size?
OS Fund typically joins rounds of $1.6M–$6M at Seed, $5M–$32M at Series A and $12M–$53M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds OS Fund participates in.
How do I contact OS Fund?
Public channels for OS Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at OS Fund?
The team at OS Fund includes Bryan Johnson (Co-Founder & General Partner), Daniel Robinson (Partner) and Jonathan Yaffe (Chief Financial Officer), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
